Objective: : Recently, thoracoscopic techniques have been used to perform transmyocardial laser revascularization (TMR) in patients who are not suitable candidates for coronary artery bypass graft (CABG) surgery or percutaneous coronary interventions. Whether or not prior CABG contraindicates a port access-only approach to TMR is unclear. This study compares patients with and without prior CABG who have undergone thoracoscopic TMR.
Methods: : Between May 2003 and October 2005, 23 consecutive patients (6 without prior CABG, group A; and 17 with prior CABG, group B) underwent thoracoscopic TMR, using a holmium:yttrium-aluminum-garnet (Ho:YAG) laser system. Either 3 or 4 port incisions (each ≤2 cm in length) were used, depending on the patient's anatomy. Procedural success was defined as the ability to create all intended channels without conversion to thoracotomy.
Results: : Patient demographics were not significantly different between group A and group B (mean age, 65.8 ± 4.3 years versus 67.4 ± 2.4 years, Canadian Cardiovascular Society angina class 3.7 ± 0.2 versus 3.9 ± 0.1, and Parsonnet score 12.0 ± 3.2 versus 20.5 ± 2.4). Fourteen (82.4%) group B patients had a prior left internal mammary artery to left anterior descending artery graft, of which 12 (85.7%) were patent. One patient in group A had an airway injury at intubation that led to an extended hospital stay of 30 days. One patient in group A (16.7%) and one patient in group B (5.9%) required a blood transfusion (P = NS). Adhesion lysis time in group B ranged from 0 to 68 minutes (mean, 27 ± 5.6 minutes). Neither group had a conversion to thoracotomy or any deaths through a mean combined follow-up of 12 months.
Conclusions: : A port access approach is safe and reproducible for patients who are candidates for sole therapy TMR. Prior CABG, including patent grafts, is not a contraindication to thoracoscopic TMR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IMI.0b013e318065b109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial.
JAMA Cardiol
January 2025
Brigham and Women's Hospital Heart and Vascular Center, Center for Advanced Heart Disease, Harvard Medical School, Boston, Massachusetts.
Importance: The Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure (ARIES-HM3) study demonstrated that aspirin may be safely eliminated from the antithrombotic regimen after HeartMate 3 (HM3 [Abbott Cardiovascular]) left ventricular assist device (LVAD) implantation. This prespecified analysis explored whether conditions requiring aspirin (prior percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG], stroke, or peripheral vascular disease [PVD]) would influence outcomes differentially with aspirin avoidance.
Objective: To analyze aspirin avoidance on hemocompatibility-related adverse events (HRAEs) at 1 year after implant in patients with a history of CABG, PCI, stroke, or PVD.
Introduction: Lung transplantation (LT) is a lifesaving procedure in patients with end stage lung failure. The prevalence of coronary artery disease (CAD) in patients with lung disease is comparably high, and coronary angiography is widely used for coronary anatomy assessment prior to LT. Detection of significant CAD usually results in revascularization to minimize post-transplant cardiovascular events.
View Article and Find Full Text PDFCoping With the Crash: Intraoperative Management of Ventricular Wall Rupture During Coronary Artery Bypass Graft Surgery.
Cureus
December 2024
Anesthesiology, University of Maryland Medical Center, Baltimore, USA.
Article Synopsis
- Left ventricular (LV) free wall rupture is a serious and often deadly outcome of a heart attack, specifically after an acute myocardial infarction.
- A case is presented involving an elderly woman who experienced this rupture following anesthesia induction for a heart surgery, having suffered a heart attack just days earlier.
- The case underscores the importance of recognizing symptoms and managing severe low blood pressure during surgery, while also discussing the uncommon ways this rupture can manifest and how to effectively treat it.
Predictors of the Need for Permanent Pacemaker Implantation After Surgical Aortic Valve Replacement with a Biological Prosthesis and the Effect on Long-Term Survival.
J Cardiovasc Dev Dis
December 2024
Faculty of Medicine & Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
The need for a permanent pacemaker (PPM) implantation after surgical aortic valve implantation (SAVR) is a recognized postoperative complication, with potentially long-term reduced survival. From 1987 to 2017, 2500 consecutive patients underwent SAVR with a biological valve with or without concomitant procedures such as CABG or mitral valve repair. Mechanical valves or valves in another position were excluded.
View Article and Find Full Text PDFReferral Networks, Racial Inequity, and Hospital Quality for Open Heart Surgery.
Circ Cardiovasc Qual Outcomes
December 2024
RAND Corporation, Santa Monica, CA (C.B.G., C.L.D., S.Z., M.S., L.J.M., I.P.).
Background: Differences in the quality of hospitals where Black and White patients receive coronary artery bypass grafting (CABG) surgery have been documented. We examined the contributions of physician networks to the gap.
Methods: This was a cross-sectional study of all Medicare fee-for-service Black and White patients undergoing elective CABG during 2017 to 2019; the primary care physicians and cardiologists treating them for 12 months before surgery (the patients' physician network); and CABG-performing hospitals within 100 miles of each patient.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!